Genetic and clinical characteristics of primary hemophagocytic lymphohistiocytosis in children.

To analyze the genetic variation and prognosis of primary hemophagocytic lymphohistiocytosis (pHLH) in children and the clinical features of isolated central nervous system HLH (CNS-HLH). We retrospectively analyzed the clinical and genetic data of 480 HLH children admitted to our hospital from September 2017 to September 2022. There were 66 patients (13.75%) with pHLH, and the median age was 3.21 years (0.17-12.92 years). Variants in UNC13D (22/66, 33.33%), PRF1 (20/66, 30.30%) and XIAP (11/66, 16.67%) were the most common. More CNS involvement was observed in pHLH patients than in secondary hemophagocytic lymphohistiocytosis (sHLH) patients (50% vs. 25.3%, P = 0.001). Eight pHLH patients had isolated CNS-HLH at onset, which progressed to systemic HLH within 10-30 days to several years. Among them, five patients who underwent hematopoietic stem cell transplantation (HSCT) survived without CNS sequelae, and the three patients who did not undergo HSCT died of disease progression or recurrence. Determination of natural killer (NK) cell cytotoxicity and CD107a levels had low sensitivity and specificity in the diagnosis of pHLH, especially in patients with PRF1 and XIAP mutations. The 3-year overall survival (OS) was significantly lower in pHLH patients than in sHLH patients (74.5% ± 14.7% vs. 89.2% ± 3.53%, P = 0.021) and in patients with CNS involvement than in those without (53.8% ± 26.07% vs. 94.4% ± 10.58%, P = 0.012). There was a significant difference in OS among pHLH patients with different gene variants (P = 0.032); patients with PRF1 variants had poor 3-year OS, and patients with XIAP variants had good 3-year OS (50% ± 28.22% and 100%, respectively). pHLH patients with distinct variants have different prognoses. Isolated CNS-HLH patients are easily misdiagnosed, and HSCT may be beneficial for these patients. Determination of NK cell cytotoxicity and CD107a levels cannot precisely distinguish pHLH from sHLH.

Zhao C ，Zhang Q ，Zhang R ，Lian H ，Ma H ，Zhao X ，Li Z ... -  《-》

Treatment of pediatric primary hemophagocytic lymphohistiocytosis with the HLH-94/2004 regimens and hematopoietic stem cell transplantation in China.

Ma H ，Zhang R ，Zhang L ，Wei A ，Zhao X ，Yang Y ，Liu W ，Li Z ，Qin M ，Wang T ... -  《-》

Genotype characteristics and immunological indicator evaluation of 311 hemophagocytic lymphohistiocytosis cases in China.

Zhang J ，Sun Y ，Shi X ，Zhang R ，Wang Y ，Xiao J ，Cao J ，Gao Z ，Wang J ，Wu L ，Wei W ，Wang Z ... -  《-》

Genetic characterization of pediatric primary hemophagocytic lymphohistiocytosis in China: a single-center study.

Zhang L ，Li Z ，Liu W ，Ma H ，Wang T ，Zhang R ... -  《-》

The occurrence and treatment of hemophagocytic lymphohistiocytosis caused by multiple factors: a case report and literature review.

Zhuo W ，Hao D ，Tong Y ，Wu W ，Bao S ，Huang K ，Ling Y ，Zhu H ，Sun Z ... -  《-》